172 related articles for article (PubMed ID: 24625997)
1. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia.
Sezer S; Karakan S; Atesagaoglu B; Acar FN
Saudi J Kidney Dis Transpl; 2014 Mar; 25(2):316-20. PubMed ID: 24625997
[TBL] [Abstract][Full Text] [Related]
2. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Zhang X; Wan D; Yang G; Peng Q; Wang X
Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
[TBL] [Abstract][Full Text] [Related]
4. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.
Kanbay M; Ozkara A; Selcoki Y; Isik B; Turgut F; Bavbek N; Uz E; Akcay A; Yigitoglu R; Covic A
Int Urol Nephrol; 2007; 39(4):1227-33. PubMed ID: 17701281
[TBL] [Abstract][Full Text] [Related]
6. Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.
Watanabe K; Nakayama M; Yamamoto T; Yamada G; Sato H; Miyazaki M; Ito S
PLoS One; 2021; 16(3):e0249240. PubMed ID: 33765101
[TBL] [Abstract][Full Text] [Related]
7. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
Ghane Sharbaf F; Assadi F
Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
[TBL] [Abstract][Full Text] [Related]
8. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.
Yelken B; Caliskan Y; Gorgulu N; Altun I; Yilmaz A; Yazici H; Oflaz H; Yildiz A
Clin Nephrol; 2012 Apr; 77(4):275-82. PubMed ID: 22445470
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
[TBL] [Abstract][Full Text] [Related]
10. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
11. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P
J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299
[TBL] [Abstract][Full Text] [Related]
12. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
Bartáková V; Kuricová K; Pácal L; Nová Z; Dvořáková V; Švrčková M; Malúšková D; Svobodová I; Řehořová J; Svojanovský J; Olšovský J; Bělobrádková J; Kaňková K
J Diabetes Complications; 2016; 30(7):1300-7. PubMed ID: 27324705
[TBL] [Abstract][Full Text] [Related]
13. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Goicoechea M; de Vinuesa SG; Verdalles U; Ruiz-Caro C; Ampuero J; Rincón A; Arroyo D; Luño J
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1388-93. PubMed ID: 20538833
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
[TBL] [Abstract][Full Text] [Related]
15. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
[TBL] [Abstract][Full Text] [Related]
17. J-shaped mortality relationship for uric acid in CKD.
Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
[TBL] [Abstract][Full Text] [Related]
18. Association of conicity index and renal progression in pre-dialysis chronic kidney disease.
Sezer S; Karakan S; Acar NÖ
Ren Fail; 2012; 34(2):165-70. PubMed ID: 22250986
[TBL] [Abstract][Full Text] [Related]
19. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Allopurinol on Renal Function.
Krishnamurthy A; Lazaro D; Stefanov DG; Blumenthal D; Gerber D; Patel S
J Clin Rheumatol; 2017 Jan; 23(1):1-5. PubMed ID: 28002149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
